What urgent evaluation and treatment steps are indicated for a patient with macrocytic anemia, leukocytosis, and marked thrombocytosis based on the CBC values (WBC 12.1 ×10⁹/L, hemoglobin 10.6 g/dL, hematocrit 33.6 %, MCV 109 fL, MCH 34.4 pg, RDW 15.7 %, platelets 706 ×10⁹/L, absolute neutrophil count 9.34 ×10⁹/L, absolute monocyte count 1.22 ×10⁹/L)?

Urgent Evaluation for Suspected Myeloproliferative Neoplasm

This patient requires immediate evaluation for a myeloproliferative neoplasm (MPN), specifically polycythemia vera (PV) or essential thrombocythemia (ET), with JAK2 mutation testing as the first-line diagnostic test, followed by bone marrow biopsy if initial workup is inconclusive.

Critical Laboratory Abnormalities

The CBC reveals a concerning triad:

• Macrocytic anemia (MCV 109 fL, Hb 10.6 g/dL)
• Marked thrombocytosis (platelets 706 × 10⁹/L)
• Leukocytosis with neutrophilia (WBC 12.1 × 10⁹/L, ANC 9.34 × 10⁹/L)

This combination strongly suggests an MPN rather than isolated nutritional deficiency or other benign causes 1.

Immediate Diagnostic Workup

First-Tier Testing (Order Immediately):

1. JAK2 V617F mutation testing - Present in >95% of PV cases and helps distinguish primary from secondary causes 1

2. Vitamin B12 and folate levels - To exclude megaloblastic causes of macrocytosis, though the thrombocytosis makes this less likely 2

3. Peripheral blood smear review - Look for:

• Megakaryocytic fragments
• Giant platelets
• Nucleated RBCs
• Blast cells (critical to exclude acute leukemia)

4. Comprehensive metabolic panel - Including liver function tests (AST, ALT, bilirubin) to exclude liver disease as cause of macrocytosis 2

5. TSH - To exclude hypothyroidism 2

6. Reticulocyte count - To assess bone marrow response 3

Second-Tier Testing (If JAK2 Positive or High Clinical Suspicion):

7. Bone marrow biopsy with cytogenetics - Essential if:

• JAK2 mutation is positive
• Cytopenias develop alongside thrombocytosis
• Any concern for myelodysplastic syndrome (MDS) or myelofibrosis 4, 2

8. Erythropoietin level - Typically low in PV 1

9. BCR-ABL testing - To exclude chronic myeloid leukemia

Risk Stratification and Urgent Treatment Considerations

If Polycythemia Vera is Confirmed:

Immediate thrombosis risk assessment:

• Age ≥60 years OR prior thrombotic event = high-risk 5, 6
• Requires cytoreductive therapy in addition to phlebotomy

Start aspirin 81-100 mg daily immediately (unless contraindications exist) 5, 6, 1

Critical Thromboembolic Risk Factors:

The platelet count of 706 × 10⁹/L is concerning but below the extreme thrombocytosis threshold (≥1500 × 10⁹/L) that would indicate urgent cytoreduction per guidelines 5. However, the WBC of 12.1 × 10⁹/L exceeds the threshold (>10 × 10⁹/L) that constitutes an indication for cytoreductive therapy 6.

Uncontrolled myeloproliferation criteria met:

• Platelet count >400 × 10⁹/L AND WBC >10 × 10⁹/L indicates need for cytoreduction 6

Treatment Algorithm Based on Diagnosis

If PV Confirmed:

1. Start aspirin 81-100 mg daily 5, 1

2. Assess hematocrit target:

• If hematocrit >45%: Begin phlebotomy (300-450 mL weekly or twice weekly) 5
• Target hematocrit <45% to reduce thrombosis risk 5, 1

3. Initiate cytoreductive therapy if:

• Age ≥60 years
• Prior thrombotic event
• WBC >15 × 10⁹/L (approaching this threshold at 12.1)
• Platelet count >1500 × 10⁹/L
• Symptomatic or progressive splenomegaly 5

First-line cytoreductive options:

• Hydroxyurea (use cautiously in younger patients) 5, 6
• Recombinant interferon-alpha (preferred in younger patients) 5

If Essential Thrombocythemia Confirmed:

Risk stratification using revised IPSET-Thrombosis score 6

High-risk patients require cytoreduction plus aspirin

Critical Pitfalls to Avoid

1. Do NOT delay JAK2 testing - This is the key diagnostic test that will guide all subsequent management 1

2. Do NOT assume nutritional deficiency - While macrocytosis suggests B12/folate deficiency, the concurrent thrombocytosis and leukocytosis point to MPN 2

3. Do NOT wait for symptoms to worsen - Thrombotic events can occur before diagnosis in 16% (arterial) and 7% (venous) of PV patients 1

4. Do NOT overlook MDS - In patients with unexplained macrocytosis, 11.6% develop primary bone marrow disorders within median follow-up of 4 years 4. The combination with thrombocytosis makes MPN more likely than MDS, but bone marrow biopsy may be needed for definitive diagnosis.

5. Monitor for extreme thrombocytosis - Platelet counts ≥1000 × 10⁹/L can cause acquired von Willebrand disease and paradoxical bleeding risk 1

Monitoring Strategy

If diagnosis remains unclear after initial workup:

• Repeat CBC every 6 months 4
• Bone marrow biopsy if cytopenias develop or counts worsen 4
• Mean time to diagnosis of bone marrow disorder in unexplained macrocytosis is 31.6 months 4

Refer to hematology immediately if JAK2 positive or if bone marrow biopsy shows clonal disorder 6, 2